Inavolisib
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Inavolisib
- DrugBank Accession Number
- DB15275
- Background
Inavolisib (GDC-0077) is under investigation in clinical trial NCT03006172 (To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 407.378
Monoisotopic: 407.140510438 - Chemical Formula
- C18H19F2N5O4
- Synonyms
- (2S)-2-((2-((4S)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl)-5,6-dihydroimidazo(1,2-D)(1,4)benzoxazepin-9-yl)amino)propanamide
- propanamide, 2-((2-((4S)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl)-5,6-dihydroimidazo(1,2-D)(1,4)benzoxazepin-9-yl)amino)-, (2S)-
- External IDs
- GDC 0077
- GDC-0077
- RG-6114
- RG6114
- RO-7113755
- RO7113755
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- L4C1UY2NYH
- CAS number
- 2060571-02-8
- InChI Key
- SGEUNORSOZVTOL-CABZTGNLSA-N
- InChI
- InChI=1S/C18H19F2N5O4/c1-9(16(21)26)22-10-2-3-11-13(6-10)28-5-4-24-7-14(23-17(11)24)25-12(15(19)20)8-29-18(25)27/h2-3,6-7,9,12,15,22H,4-5,8H2,1H3,(H2,21,26)/t9-,12-/m0/s1
- IUPAC Name
- (2S)-2-({4-[(4S)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-9-oxa-3,6-diazatricyclo[8.4.0.0^{2,6}]tetradeca-1(14),2,4,10,12-pentaen-12-yl}amino)propanamide
- SMILES
- C[C@H](NC1=CC=C2C3=NC(=CN3CCOC2=C1)N1[C@@H](COC1=O)C(F)F)C(N)=O
References
- General References
- Not Available
- External Links
- ChemSpider
- 59718498
- BindingDB
- 295665
- ChEMBL
- CHEMBL4650215
- ZINC
- ZINC000669678973
- PDBe Ligand
- X3N
- PDB Entries
- 8exv / 8tdu / 8tgd
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Recruiting Treatment Breast Cancer 1 3 Recruiting Treatment Metastatic Breast Cancer 1 2 Active Not Recruiting Treatment Advanced Unresectable or Metastatic Solid Malignancy 1 2 Not Yet Recruiting Treatment Breast Cancer 1 2 Recruiting Treatment Breast Cancer / Triple-Negative Breast Cancer 1 2 Recruiting Treatment HER2/Neu-positive Breast Cancer 1 2 Recruiting Treatment Metastatic or Locally Advanced Malignancies 1 2 Recruiting Treatment Ovarian Cancer 1 2 Recruiting Treatment Solid Tumors 1 2 Recruiting Treatment Stage I Breast Cancer 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.517 mg/mL ALOGPS logP 1.49 ALOGPS logP 1.16 Chemaxon logS -2.9 ALOGPS pKa (Strongest Acidic) 15.19 Chemaxon pKa (Strongest Basic) 3.32 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 111.71 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 108.28 m3·mol-1 Chemaxon Polarizability 39.18 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at May 20, 2019 15:06 / Updated at February 03, 2023 08:02